Dr. Hakim said the sales of the twice daily OC would generate 500 million in sales. Using a reasonable 30% net profit estimate. ELTP will generate 150 million in profit off of one drug. Which would be .27 EPS. Giving ELTP a low P/E ratio (for a biotech with 15 drugs in its pipeline) of 15 ELTP will be worth $4.00 per share. This would be a 10 bagger from here in less than 24 months. Even if the new A/S became O/S because a parter has not been found ELTP would still be worth $2.37 a share. This is off of 1 drug. There are 2 others that should hit the market in this time frame earning more revenue as well as the 12 ANDA's.
Market Data 
Markets 
AI
